binimetinib

1 Drug classified under this active ingredient

Kinase Inhibitor. binimetinib 15 mg.
FC Tab. 180X 15 mg
Recommended dosage is 45 mg orally taken twice daily, approx. 12 hs. apart, in combin. with encorafenib until dis. progress. or unacceptable tox.
BRAF V600E or V600K Mutation-Posit. Unresectable or Metast. Melanoma in combin. with encorafenib.
BRAF V600E Mutation-Posit. metast. non-small cell lung cancer (NSCLC) adenocarcinoma in combin. with encorafenib.
C/I:Hypersens.